Hartford Investment Management Co. Decreases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Hartford Investment Management Co. lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.7% during the fourth quarter, HoldingsChannel.com reports. The fund owned 6,503 shares of the biopharmaceutical company’s stock after selling 183 shares during the quarter. Hartford Investment Management Co.’s holdings in Regeneron Pharmaceuticals were worth $4,632,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in REGN. Mizuho Securities USA LLC lifted its holdings in Regeneron Pharmaceuticals by 625.5% in the third quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock valued at $62,382,000 after acquiring an additional 51,162 shares during the period. Principal Financial Group Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 1.7% in the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock worth $181,961,000 after purchasing an additional 2,828 shares during the period. Simplify Asset Management Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 50.8% in the third quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock worth $10,082,000 after buying an additional 3,231 shares during the last quarter. Golden State Equity Partners boosted its holdings in shares of Regeneron Pharmaceuticals by 1,479.1% in the fourth quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company’s stock worth $967,000 after buying an additional 1,272 shares during the last quarter. Finally, Catalytic Wealth RIA LLC bought a new stake in Regeneron Pharmaceuticals during the third quarter valued at approximately $1,334,000. 83.31% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Bernstein Bank cut their price objective on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Evercore ISI cut their price target on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. UBS Group downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Canaccord Genuity Group assumed coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price for the company. Finally, Leerink Partners raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $762.00 to $834.00 in a report on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $663.86 on Thursday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The firm’s fifty day moving average is $712.69 and its 200 day moving average is $903.47. The company has a market cap of $72.95 billion, a price-to-earnings ratio of 17.34, a PEG ratio of 2.38 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business’s revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the company earned $11.86 EPS. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 36.67 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.53%. The ex-dividend date of this dividend is Thursday, February 20th.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.